BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okuno T, Yashiro M, Masuda G, Togano S, Kuroda K, Miki Y, Hirakawa K, Ohsawa M, Wanibuchi H, Ohira M. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14. Ann Surg Oncol 2019;26:1093-102. [PMID: 30652228 DOI: 10.1245/s10434-018-07145-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Miki Y, Yashiro M, Moyano-Galceran L, Sugimoto A, Ohira M, Lehti K. Crosstalk Between Cancer Associated Fibroblasts and Cancer Cells in Scirrhous Type Gastric Cancer. Front Oncol 2020;10:568557. [PMID: 33178597 DOI: 10.3389/fonc.2020.568557] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Yashiro M, Kuroda K, Masuda G, Okuno T, Miki Y, Yamamoto Y, Sera T, Sugimoto A, Kushiyama S, Nishimura S, Togano S, Ohira M. Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer. Sci Rep 2021;11:4698. [PMID: 33633310 DOI: 10.1038/s41598-021-84107-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang D, Yang L, Yu W, Zhang Y. Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors. Expert Opin Investig Drugs 2019;28:903-16. [PMID: 31560229 DOI: 10.1080/13543784.2019.1672655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
4 Kuroda K, Yashiro M, Miki Y, Sera T, Yamamoto Y, Sugimoto A, Nishimura S, Kushiyama S, Togano S, Okuno T, Ohira M. Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor. Cancer Sci 2020;111:4500-9. [PMID: 32946655 DOI: 10.1111/cas.14654] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Yasui W. Is FGFR2 a Suitable Target to Treat Scirrhous-Type Gastric Cancer? Ann Surg Oncol 2019;26:926-7. [PMID: 30623340 DOI: 10.1245/s10434-018-07146-1] [Reference Citation Analysis]
6 Yashiro M, Kinoshita H, Tsujio G, Fukuoka T, Yamamoto Y, Sera T, Sugimoto A, Nishimura S, Kushiyama S, Togano S, Kuroda K, Toyokawa T, Ohira M. SDF1α/CXCR4 axis may be associated with the malignant progression of gastric cancer in the hypoxic tumor microenvironment. Oncol Lett 2021;21:38. [PMID: 33262830 DOI: 10.3892/ol.2020.12299] [Reference Citation Analysis]
7 Ooki A, Yamaguchi K. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer 2021. [PMID: 34398359 DOI: 10.1007/s10120-021-01235-z] [Reference Citation Analysis]
8 Nishimura S, Yashiro M, Sera T, Yamamoto Y, Kushitani Y, Sugimoto A, Kushiyama S, Togano S, Kuroda K, Okuno T, Murakami Y, Ohira M. Serine threonine kinase 11/liver kinase B1 mutation in sporadic scirrhous-type gastric cancer cells. Carcinogenesis 2020;41:1616-23. [PMID: 32236518 DOI: 10.1093/carcin/bgaa031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kasurinen A, Gramolelli S, Hagström J, Laitinen A, Kokkola A, Miki Y, Lehti K, Yashiro M, Ojala PM, Böckelman C, Haglund C. High tissue MMP14 expression predicts worse survival in gastric cancer, particularly with a low PROX1. Cancer Med 2019;8:6995-7005. [PMID: 31560170 DOI: 10.1002/cam4.2576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]